176 related articles for article (PubMed ID: 22642177)
1. [Oncolytic parvoviruses. A new approaches for cancer therapy].
Loktev VB; Ivan'kina TIu; Netesov SV; Chumakov PM
Vestn Ross Akad Med Nauk; 2012; (2):42-7. PubMed ID: 22642177
[TBL] [Abstract][Full Text] [Related]
2. Oncolytic parvoviruses as cancer therapeutics.
Rommelaere J; Geletneky K; Angelova AL; Daeffler L; Dinsart C; Kiprianova I; Schlehofer JR; Raykov Z
Cytokine Growth Factor Rev; 2010; 21(2-3):185-95. PubMed ID: 20211577
[TBL] [Abstract][Full Text] [Related]
3. Phase I/IIa study of intratumoral/intracerebral or intravenous/intracerebral administration of Parvovirus H-1 (ParvOryx) in patients with progressive primary or recurrent glioblastoma multiforme: ParvOryx01 protocol.
Geletneky K; Huesing J; Rommelaere J; Schlehofer JR; Leuchs B; Dahm M; Krebs O; von Knebel Doeberitz M; Huber B; Hajda J
BMC Cancer; 2012 Mar; 12():99. PubMed ID: 22436661
[TBL] [Abstract][Full Text] [Related]
4. Oncolytic H-1 Parvovirus Shows Safety and Signs of Immunogenic Activity in a First Phase I/IIa Glioblastoma Trial.
Geletneky K; Hajda J; Angelova AL; Leuchs B; Capper D; Bartsch AJ; Neumann JO; Schöning T; Hüsing J; Beelte B; Kiprianova I; Roscher M; Bhat R; von Deimling A; Brück W; Just A; Frehtman V; Löbhard S; Terletskaia-Ladwig E; Fry J; Jochims K; Daniel V; Krebs O; Dahm M; Huber B; Unterberg A; Rommelaere J
Mol Ther; 2017 Dec; 25(12):2620-2634. PubMed ID: 28967558
[TBL] [Abstract][Full Text] [Related]
5. Immunotherapeutic Potential of Oncolytic H-1 Parvovirus: Hints of Glioblastoma Microenvironment Conversion towards Immunogenicity.
Angelova AL; Barf M; Geletneky K; Unterberg A; Rommelaere J
Viruses; 2017 Dec; 9(12):. PubMed ID: 29244745
[TBL] [Abstract][Full Text] [Related]
6. Combined oncolytic and vaccination activities of parvovirus H-1 in a metastatic tumor model.
Raykov Z; Grekova S; Galabov AS; Balboni G; Koch U; Aprahamian M; Rommelaere J
Oncol Rep; 2007 Jun; 17(6):1493-9. PubMed ID: 17487410
[TBL] [Abstract][Full Text] [Related]
7. Double-faceted mechanism of parvoviral oncosuppression.
Geletneky K; Nüesch JP; Angelova A; Kiprianova I; Rommelaere J
Curr Opin Virol; 2015 Aug; 13():17-24. PubMed ID: 25841215
[TBL] [Abstract][Full Text] [Related]
8. Fluorescence In Situ Hybridization (FISH) Detection of Viral Nucleic Acids in Oncolytic H-1 Parvovirus-Treated Human Brain Tumors.
Kiprianova I; Just A; Leuchs B; Rommelaere J; Angelova AL
Methods Mol Biol; 2020; 2058():295-306. PubMed ID: 31486047
[TBL] [Abstract][Full Text] [Related]
9. Oncolytic parvoviruses: from basic virology to clinical applications.
Marchini A; Bonifati S; Scott EM; Angelova AL; Rommelaere J
Virol J; 2015 Jan; 12():6. PubMed ID: 25630937
[TBL] [Abstract][Full Text] [Related]
10. Virotherapy of digestive tumors with rodent parvovirus: overview and perspectives.
Akladios C; Aprahamian M
Expert Opin Biol Ther; 2016; 16(5):645-53. PubMed ID: 26855087
[TBL] [Abstract][Full Text] [Related]
11. Activation of the human immune system via toll-like receptors by the oncolytic parvovirus H-1.
Sieben M; Schäfer P; Dinsart C; Galle PR; Moehler M
Int J Cancer; 2013 Jun; 132(11):2548-56. PubMed ID: 23151948
[TBL] [Abstract][Full Text] [Related]
12. Pediatric and Adult High-Grade Glioma Stem Cell Culture Models Are Permissive to Lytic Infection with Parvovirus H-1.
Josupeit R; Bender S; Kern S; Leuchs B; Hielscher T; Herold-Mende C; Schlehofer JR; Dinsart C; Witt O; Rommelaere J; Lacroix J
Viruses; 2016 May; 8(5):. PubMed ID: 27213425
[TBL] [Abstract][Full Text] [Related]
13. Immune Conversion of Tumor Microenvironment by Oncolytic Viruses: The Protoparvovirus H-1PV Case Study.
Marchini A; Daeffler L; Pozdeev VI; Angelova A; Rommelaere J
Front Immunol; 2019; 10():1848. PubMed ID: 31440242
[TBL] [Abstract][Full Text] [Related]
14. Preclinical Testing of an Oncolytic Parvovirus in Ewing Sarcoma: Protoparvovirus H-1 Induces Apoptosis and Lytic Infection In Vitro but Fails to Improve Survival In Vivo.
Lacroix J; Kis Z; Josupeit R; Schlund F; Stroh-Dege A; Frank-Stöhr M; Leuchs B; Schlehofer JR; Rommelaere J; Dinsart C
Viruses; 2018 Jun; 10(6):. PubMed ID: 29865280
[TBL] [Abstract][Full Text] [Related]
15. Improved killing of human high-grade glioma cells by combining ionizing radiation with oncolytic parvovirus H-1 infection.
Geletneky K; Hartkopf AD; Krempien R; Rommelaere J; Schlehofer JR
J Biomed Biotechnol; 2010; 2010():350748. PubMed ID: 20224643
[TBL] [Abstract][Full Text] [Related]
16. Activation of the human immune system by chemotherapeutic or targeted agents combined with the oncolytic parvovirus H-1.
Moehler M; Sieben M; Roth S; Springsguth F; Leuchs B; Zeidler M; Dinsart C; Rommelaere J; Galle PR
BMC Cancer; 2011 Oct; 11():464. PubMed ID: 22029859
[TBL] [Abstract][Full Text] [Related]
17. Oncolytic H-1 Parvovirus Hijacks Galectin-1 to Enter Cancer Cells.
Ferreira T; Kulkarni A; Bretscher C; Nazarov PV; Hossain JA; Ystaas LAR; Miletic H; Röth R; Niesler B; Marchini A
Viruses; 2022 May; 14(5):. PubMed ID: 35632759
[TBL] [Abstract][Full Text] [Related]
18. SMAD4: a predictive marker of PDAC cell permissiveness for oncolytic infection with parvovirus H-1PV.
Dempe S; Stroh-Dege AY; Schwarz E; Rommelaere J; Dinsart C
Int J Cancer; 2010 Jun; 126(12):2914-27. PubMed ID: 19856310
[TBL] [Abstract][Full Text] [Related]
19. [Oncolytic properties of some orthopoxviruses, adenoviruses and parvoviruses in human glioma cells].
Razumov IA; Sviatchenko VA; Protopopova EV; Kochneva GV; Kiselev NN; Gubanova NV; Shilov AG; Mordvinov VA; Netesov SV; Chumakov PM; Loktev VB
Vestn Ross Akad Med Nauk; 2013; (12):4-8. PubMed ID: 24741936
[TBL] [Abstract][Full Text] [Related]
20. Immune cells participate in the oncosuppressive activity of parvovirus H-1PV and are activated as a result of their abortive infection with this agent.
Grekova S; Aprahamian M; Giese N; Schmitt S; Giese T; Falk CS; Daeffler L; Cziepluch C; Rommelaere J; Raykov Z
Cancer Biol Ther; 2010 Dec; 10(12):1280-9. PubMed ID: 21124075
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
